BR112016017996A2 - 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso - Google Patents

6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso

Info

Publication number
BR112016017996A2
BR112016017996A2 BR112016017996A BR112016017996A BR112016017996A2 BR 112016017996 A2 BR112016017996 A2 BR 112016017996A2 BR 112016017996 A BR112016017996 A BR 112016017996A BR 112016017996 A BR112016017996 A BR 112016017996A BR 112016017996 A2 BR112016017996 A2 BR 112016017996A2
Authority
BR
Brazil
Prior art keywords
compounds
carboxamides
heteroaryloxy
quinoline
aryloxy
Prior art date
Application number
BR112016017996A
Other languages
English (en)
Inventor
Bogdan Andrew
D Cowart Marlon
A Degoey David
K Jinkerson Tammie
R Koenig John
E Kort Michael
Liu Bo
A Matulenko Mark
W Nelson Derek
V Patel Meena
PELTIER Hillary
J Scanio Marc
D Wakefield Brian
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112016017996A2 publication Critical patent/BR112016017996A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

6-HETEROARILOXI- OR 6-ARILOXI-QUINOLINA-2-CARBOXAMIDAS E MÉTODO DE USO. A presente invenção refere-se a certos compostos de Fórmula (I) e seus sais, ésteres, amidas ou formas radiomarcadas farmaceuticamente aceitáveis, em que R1, R2 e R3 são como definidos no relatório descritivo, que são úteis para tratar condições ou transtornos evitados ou melhorados por canais de sódio dependentes da voltagem, por exemplo, Nav1.7 e/ou Nav1.8. São descritos métodos para produzir os compostos. Além disso, a presente invenção revela composições farmacêuticas dos compostos de Fórmula (I) e métodos para utilizar tais compostos e composições.
BR112016017996A 2014-02-06 2015-02-04 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso BR112016017996A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936397P 2014-02-06 2014-02-06
PCT/US2015/014380 WO2015119998A1 (en) 2014-02-06 2015-02-04 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof

Publications (1)

Publication Number Publication Date
BR112016017996A2 true BR112016017996A2 (pt) 2017-08-08

Family

ID=52484589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017996A BR112016017996A2 (pt) 2014-02-06 2015-02-04 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso

Country Status (14)

Country Link
US (3) US9452986B2 (pt)
EP (1) EP3102569A1 (pt)
JP (1) JP6532474B2 (pt)
KR (1) KR20160118345A (pt)
CN (1) CN106458985B (pt)
AU (1) AU2015214366B2 (pt)
BR (1) BR112016017996A2 (pt)
CA (1) CA2938719A1 (pt)
HK (1) HK1231471A1 (pt)
IL (1) IL247014A0 (pt)
MX (1) MX2016010056A (pt)
RU (1) RU2016135637A (pt)
SG (1) SG11201606367YA (pt)
WO (1) WO2015119998A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TR201815683T4 (tr) 2014-01-13 2018-11-21 Aurigene Discovery Tech Ltd Irak4 inhibitörleri olarak bisiklik heterosiklil türevleri.
MX2016010056A (es) * 2014-02-06 2016-11-15 Abbvie Inc 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
MX2016017147A (es) * 2014-06-20 2017-06-07 Aurigene Discovery Tech Ltd Compuestos de indazole substituidos como inhibidores de irak4.
US9611262B2 (en) * 2014-09-11 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
CA3090492C (en) 2015-10-07 2023-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Crmp2 sumoylation inhibitors and uses thereof
ES2829636T3 (es) * 2015-10-09 2021-06-01 Abbvie Overseas Sarl Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso
CN110337436A (zh) 2016-12-22 2019-10-15 拜耳作物科学股份公司 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途
SI3600270T1 (sl) 2017-03-31 2023-10-30 Aurigene Oncology Limited Spojine in sestavki za zdravljenje hematoloških motenj
MX2019015895A (es) * 2017-06-30 2020-02-07 Bayer Animal Health Gmbh Nuevos derivados de azaquinolina.
EP3704108B1 (en) 2017-10-31 2024-04-24 Curis, Inc. Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer
EP3851436A4 (en) 2018-09-10 2022-05-18 Kaken Pharmaceutical Co., Ltd. HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING THE SAME
BR112021008741A2 (pt) 2018-11-09 2021-08-10 Vivace Therapeutics, Inc. compostos bicíclicos
SG11202107080VA (en) * 2019-01-11 2021-07-29 Naegis Pharmaceuticals Inc Leukotriene synthesis inhibitors
CN114072207B (zh) * 2019-04-16 2024-03-29 维瓦斯治疗公司 双环化合物
WO2023138599A1 (zh) * 2022-01-18 2023-07-27 成都康弘药业集团股份有限公司 芳香并环类Nav1.8抑制剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200521119A (en) 2003-08-05 2005-07-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
RU2391338C2 (ru) * 2004-10-19 2010-06-10 Ф.Хоффманн-Ля Рош Аг Производные хинолина
CN101218226A (zh) * 2005-05-16 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
GB0513692D0 (en) * 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
CN101253159B (zh) * 2005-09-01 2011-12-07 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
BRPI0719210A2 (pt) * 2006-10-12 2015-05-05 Xenon Pharmaceuticals Inc Uso de compostos espiro-oxindol como agentes terapêuticos
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
KR101605061B1 (ko) * 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
UY33372A (es) * 2010-05-10 2011-12-30 Gilead Sciences Inc ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.
CN106478497B (zh) * 2010-10-18 2020-05-08 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
TWI631105B (zh) 2013-01-31 2018-08-01 維泰克斯製藥公司 作爲鈉通道調節劑之喹啉及喹噁啉醯胺
MX2016010056A (es) * 2014-02-06 2016-11-15 Abbvie Inc 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.

Also Published As

Publication number Publication date
RU2016135637A3 (pt) 2018-08-27
US20170226062A9 (en) 2017-08-10
KR20160118345A (ko) 2016-10-11
RU2016135637A (ru) 2018-03-12
IL247014A0 (en) 2016-09-29
WO2015119998A1 (en) 2015-08-13
MX2016010056A (es) 2016-11-15
AU2015214366A1 (en) 2016-08-18
HK1231471A1 (zh) 2017-12-22
EP3102569A1 (en) 2016-12-14
CN106458985B (zh) 2019-05-03
SG11201606367YA (en) 2016-09-29
CN106458985A (zh) 2017-02-22
AU2015214366B2 (en) 2019-04-18
CA2938719A1 (en) 2015-08-13
US20150218102A1 (en) 2015-08-06
US9969693B2 (en) 2018-05-15
US20180334435A1 (en) 2018-11-22
US9452986B2 (en) 2016-09-27
JP6532474B2 (ja) 2019-06-19
JP2017505327A (ja) 2017-02-16
US20160355482A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CO2017012566A2 (es) Piridinas sustituidas y método de uso
BR112017009194A2 (pt) tetra-hidropiranos substituídos e método de uso
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
BR112018003827A2 (pt) composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição.
BR112017017349A2 (pt) composto, composição, método para tratar um distúrbio
ECSP16074478A (es) Compuestos novedosos
ECSP17069696A (es) Compuestos novedosos
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201600394A1 (ru) Трициклические соединения пиперидина
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements